Four children with thalassemia have been successfully cured using CS-101, a novel DNA base editing therapy developed by CorrectSequence Therapeutics in China, marking a significant breakthrough in genetic treatment.
Shanghai-based CorrectSequence Therapeutics has successfully treated a transfusion-dependent beta thalassaemia patient using their novel base editing therapy CS-101, marking a world first for this technology.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.